CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
皮肤 T 细胞淋巴瘤的 CAR-T 细胞研发：当前局限与潜在治疗策略
英文原题：CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.
查看英文原题
CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞治疗在B细胞恶性肿瘤中取得显著疗效，但用于T细胞淋巴瘤，尤其皮肤T细胞淋巴瘤（CTCL）的应用有限。CAR-T 治疗CTCL的障碍包括自体移植中的T细胞再生障碍、CAR-T 产品被白血病T细胞污染、CAR-T 同类相残（靶抗原也存在于正常T细胞上）以及肿瘤异质性。要应对这些关键挑战，需要通过靶向多个抗原进行创新CAR工程设计，在疗效与安全性之间取得平衡。本文讨论CAR-T 治疗当前障碍，并重点介绍治疗CTCL的潜在靶点。展望未来，我们提出开发更强效双CAR的策略，这些策略正推动CAR-T 治疗CTCL走向临床。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited. Barriers to effective CAR-T cell therapy in treating CTCL include T cell aplasia in autologous transplants, CAR-T product contamination with leukemic T cells, CAR-T fratricide (when the target antigen is present on normal T cells), and tumor heterogeneity.
To address these critical challenges, innovative CAR engineering by targeting multiple antigens to strike a balance between efficacy and safety of the therapy is necessary. In this review, we discuss the current obstacles to CAR-T cell therapy and highlight potential targets in treating CTCL. Looking forward, we propose strategies to develop more powerful dual CARs that are advancing towards the clinic in CTCL therapy.
论文信息
- 作者
- To V、Evtimov VJ、Jenkin G、Pupovac A、Trounson AO、Boyd RL
- 单位
- Cartherics Pty Ltd, Notting Hill, VIC, Australia.Australia
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36059451 · DOI 10.3389/fimmu.2022.968395
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →